"
Team:Potsdam Bioware
From 2011.igem.org
(Difference between revisions)
| (10 intermediate revisions not shown) | |||
| Line 7: | Line 7: | ||
<h2>Modification, Selection and Production of Cyclic Peptides for Therapy</h2> | <h2>Modification, Selection and Production of Cyclic Peptides for Therapy</h2> | ||
<table cellpadding="0"><td><img src="https://static.igem.org/mediawiki/2011/7/7d/UP_micrviridin_movie_final.gif"/></td> | <table cellpadding="0"><td><img src="https://static.igem.org/mediawiki/2011/7/7d/UP_micrviridin_movie_final.gif"/></td> | ||
| - | <td><p style="text-align:justify;">One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We utilized the 6.5 kb microviridin (mdn) gene cluster cloned in <i>E. coli</i> plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems adhere to the BioBrick standards. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary"><span class="bold">[more]</span></a></p> | + | <td><p style="text-align:justify;">One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We utilized the 6.5 kb microviridin (<i>mdn</i>) gene cluster cloned in <i>E. coli</i> plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems adhere to the BioBrick standards. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary"><span class="bold">[more]</span></a></p> |
</td></table> | </td></table> | ||
| Line 16: | Line 16: | ||
<!---Box on the upper left: Software---> | <!---Box on the upper left: Software---> | ||
<div class="box_home" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Software','_self');"> | <div class="box_home" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Software','_self');"> | ||
| - | <img id="topRight" src="https://static.igem.org/mediawiki/2011/ | + | <img id="topRight" src="https://static.igem.org/mediawiki/2011/b/bb/UP_home_Software1.png"> |
<h2>Software</h2> | <h2>Software</h2> | ||
<p> | <p> | ||
| Line 161: | Line 161: | ||
<div height="290px"> | <div height="290px"> | ||
<div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Data_Page','_self');"> | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Data_Page','_self');"> | ||
| - | <img class="right" src="https://static.igem.org/mediawiki/2011/ | + | <img class="right" src="https://static.igem.org/mediawiki/2011/8/84/UP_home_BioBricks.png"/> |
<h2>BioBricks</h2> | <h2>BioBricks</h2> | ||
<p class="standard"> | <p class="standard"> | ||
| Line 170: | Line 170: | ||
<!---Box on the lower left: Human Practice---> | <!---Box on the lower left: Human Practice---> | ||
<div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Safety_Ethics','_self');"> | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Safety_Ethics','_self');"> | ||
| - | <img class="right" src="https://static.igem.org/mediawiki/2011/ | + | <img class="right" src="https://static.igem.org/mediawiki/2011/1/19/UP_home_Safety.png"/> |
<h2>Safety & Ethics</h2></a> | <h2>Safety & Ethics</h2></a> | ||
| - | <p class="standard">We | + | <p class="standard">We discussed safety issues and ethic controversies in seminars and polled all members of the German parliament for their opinion on synthetic biology. Learn more about German views. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Safety_Ethics"><span class="bold">[more]</span></a></p> |
</div> | </div> | ||
<!---Box on the lower right: labjournal---> | <!---Box on the lower right: labjournal---> | ||
<div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Labjournal','_self');"> | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Labjournal','_self');"> | ||
| - | <img class="right" src="https://static.igem.org/mediawiki/2011/ | + | <img class="right" src="https://static.igem.org/mediawiki/2011/2/2a/UP_home_Labjournal.png"/> |
<h2>Labjournal</h2> | <h2>Labjournal</h2> | ||
<p> | <p> | ||
| - | All the hours spent in the lab - thinking, laughing, sweating and hoping. Here is the tour guide through our lab work.<a href="https://2011.igem.org/Team:Potsdam_Bioware/Labjournal"><span class="bold">[more]</span></a></p> | + | All the hours spent in the lab - thinking, laughing, sweating and hoping. Here is the tour guide through our lab work. We hope, you enjoy the trip. Please fasten your seat belt and mind the gap. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Labjournal"><span class="bold">[more]</span></a></p> |
</div> | </div> | ||
<!---Box on the lower right: Modeling---> | <!---Box on the lower right: Modeling---> | ||
<div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary#Modeling','_self');"> | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary#Modeling','_self');"> | ||
| - | <img class="right" src="https://static.igem.org/mediawiki/2011/ | + | <img class="right" src="https://static.igem.org/mediawiki/2011/b/bd/UP_home_Modeling.png"/> |
<h2>Modeling</h2></a> | <h2>Modeling</h2></a> | ||
<p class="standard"> | <p class="standard"> | ||
| - | + | This year we focused on systems modeling in which the reaction kinetics of the <i>in vivo</i> selection are analyzed. Read more about the predictions we were able to derive from our model. | |
<a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary#Modeling"><span class="bold">[more]</span></a></p> | <a href="https://2011.igem.org/Team:Potsdam_Bioware/Project/Summary#Modeling"><span class="bold">[more]</span></a></p> | ||
</div> | </div> | ||
| Line 208: | Line 208: | ||
| - | <html><center><div id="clustrmaps-widget"></div><script type="text/javascript">var _clustrmaps = {'url' : 'https://2011.igem.org/Team:Potsdam_Bioware', 'user' : 910340, 'server' : '2', 'id' : 'clustrmaps-widget', 'version' : 1, 'date' : '2011-07-15', 'lang' : 'en', 'corners' : 'square' };(function (){ var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www2.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x);})();</script><noscript><a href="http://www2.clustrmaps.com/user/239de404"><img src="http://www2.clustrmaps.com/stats/maps-no_clusters/2011.igem.org-Team-Potsdam_Bioware-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript | + | <html><center> |
| + | <div id="clustrmaps-widget"></div><script type="text/javascript">var _clustrmaps = {'url' : 'https://2011.igem.org/Team:Potsdam_Bioware', 'user' : 910340, 'server' : '2', 'id' : 'clustrmaps-widget', 'version' : 1, 'date' : '2011-07-15', 'lang' : 'en', 'corners' : 'square' };(function (){ var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www2.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x);})();</script><noscript><a href="http://www2.clustrmaps.com/user/239de404"><img src="http://www2.clustrmaps.com/stats/maps-no_clusters/2011.igem.org-Team-Potsdam_Bioware-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript> | ||
| - | + | <p style="font-size:xx-small; text-align:center; color:grey">primary contact: Kristian Müller, kristian@syntbio.net, http://www.syntbio.net</p> | |
| - | + | </center></html> | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </ | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </html | + | |
Latest revision as of 13:38, 16 November 2011
Modification, Selection and Production of Cyclic Peptides for Therapy
 |
One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We utilized the 6.5 kb microviridin (mdn) gene cluster cloned in E. coli plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems adhere to the BioBrick standards. [more] |
Software
BioLog – The new allround talent in the lab for your smart phone! Our app combines several features frequently used in the lab. The software stores basic protocols in your pocket - easy, handy and ready to use… [more]
Team
Nicole Albrecht
Katharina Berger
Nadja Bjelopoljak
Nadine Boehmer
Vanessa Boehmer
Jessica Eger
Steffi Sempert
Niels Weisbach
Sebastian Hanke
Sascha Ramm
Paul Kaufmann
Stefan Wahlefeld
Sandrina Heyde
Sabine Meyer
Niklas Laasch
Oliver Zimmer
Tobias Wenzel
BioBricks
Our datapage displays our systems and BioBricks in a nutshell. [more]
Our BioBricks are top-down for the mdn gene cluster and botton-up for detection and selection. [more]
Safety & Ethics
We discussed safety issues and ethic controversies in seminars and polled all members of the German parliament for their opinion on synthetic biology. Learn more about German views. [more]
Labjournal
All the hours spent in the lab - thinking, laughing, sweating and hoping. Here is the tour guide through our lab work. We hope, you enjoy the trip. Please fasten your seat belt and mind the gap. [more]
Modeling
This year we focused on systems modeling in which the reaction kinetics of the in vivo selection are analyzed. Read more about the predictions we were able to derive from our model. [more]
primary contact: Kristian Müller, kristian@syntbio.net, http://www.syntbio.net
